Depression response or remission (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression severity (acute phase, 5 ≤ 12 weeks) · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes treatment acceptability ‐ dropouts compared with psychosocial interventions (very low certainty).
1 finding from 1 review
RR 1.94 [1.12, 3.35]
Studies not reported
Very low
Child‐related outcomes · women of any age, with PND up to 12 months
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
BEV+IRI (1 RCT, 79 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+IRI (1 RCT, 79 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+VB111 (1 RCT, 128 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+VB111 (1 RCT, 128 participants) (high certainty).
1 finding from 1 review
Intervention not reported
BEV+TRC 105 (1 RCT, 49 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention leads to higher BEV+TRC 105 (1 RCT, 49 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Outcomes (5 RCTs, 1024 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
BEV(8 RCTs; 498 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
1 finding from 1 review
Intervention not reported
FOM (1 RCT, 32 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in FOM (1 RCT, 32 participants); GRADE not reported.
1 finding from 1 review
Intervention not reported
BEV+HSPPC96 1 RCTs; 53 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+HSPPC96 1 RCTs; 53 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+ONA(1 RCT; 64 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+ONA(1 RCT; 64 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+CAB (1 RCT; 58 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+CAB (1 RCT; 58 participants) (low certainty).
1 finding from 1 review
Intervention not reported
BEV+DAS (2 RCTs, 83 participants) · people with any recurrence of glioblastoma Interventions: bevacizumab (BEV) Comparison: bevacizumab 9BEV), BEV+carboplatin (CAB),…
The intervention showed no clear difference in BEV+DAS (2 RCTs, 83 participants) (high certainty).
1 finding from 1 review
ADL outcome · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
1 finding from 1 review
Secondary outcome measure: mean upper extremity function at the end of the intervention periodClinical measures of upper extremity function. Scale from: 0 to infinity. · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
1 finding from 1 review
Secondary outcome measure: lower extremity function at the end of · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
1 finding from 1 review
Secondary outcome measure: cognitive abilities at the end of · patients with improving activities of daily living, and physical and cognitive functioning at the end of follow‐up, in people after stroke
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found